Nesopine

Quick links to important sections

Nesopine

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nesopine

Nesopine is a pharmaceutical preparation that acts as a topical decongestant, primarily utilized for the temporary relief of nasal congestion and stuffiness. Its therapeutic effect is derived from its sole active ingredient, Oxymetazoline hydrochloride, which is a potent synthetic substance. The substance belongs to the general class of alpha-adrenergic agonists and has a long history of clinical use.

What Type of Medicine is Nesopine?

Nesopine belongs to the pharmacological class of sympathomimetics, functioning specifically as an alpha-adrenergic agonist. Oxymetazoline is a synthetic compound, chemically categorized as an imidazole derivative. This classification defines its fundamental function as a vasoconstrictor, meaning it targets and narrows blood vessels in the application area. As a nasal vasoconstrictor, it is used to reduce swelling in the nasal passages, which helps to open up blocked nasal breathing.

As a medicine, Nesopine is designed for topical administration, which concentrates its effect locally, differentiating it from oral agents that act systemically. This focused approach ensures the drug's action is primarily directed toward reducing the engorgement of the local mucosal membranes.

Composition, Form, and General Purpose

The product is categorized as a single-ingredient product, with its full therapeutic value provided exclusively by Oxymetazoline hydrochloride. Nesopine is typically provided in dosage forms optimized for topical use, primarily available as a nasal solution or nasal spray, which utilize an aqueous vehicle.

This composition and form allow the drug to exert its core physiological action: rapid vasoconstriction that leads to the shrinking of tissue and reduction of local swelling. By physically shrinking the swollen mucosal lining in the nose, such as during a common cold or sinusitis, Nesopine facilitates the clearing of blocked nasal passages, fulfilling its general therapeutic purpose as an effective relief for congestion. This mechanism provides targeted relief by acting directly on the affected tissues, establishing its role as a short-term aid for breathing difficulties.

What side effects are possible with Nesopine?

Possible Side Effects and Safety Information

Regulatory documents classify the safety profile of Nesopine (Oxymetazoline hydrochloride) based on local application effects, specific safety patterns tied to duration of use, and potential systemic risks.

Documented Adverse Reactions

Category Description from Regulatory Sources
Common Local Effects Application is associated with temporary discomfort in the application area, including sensations of burning, stinging, sneezing, and an increase in nasal discharge.
Duration-Related Risk Frequent or prolonged use is officially documented as potentially causing nasal congestion to recur or worsen, a pattern known as rhinitis medicamentosa.

Systemic and Special Population Safety Constraints

Nesopine is a topical sympathomimetic, and regulatory information notes the potential for systemic effects, particularly with overexposure or in individuals with specific pre-existing health conditions:

  • Serious Adverse Reactions: Documented systemic reactions include fast heartbeat and slow heartbeat. These events are noted primarily in the context of overexposure or accidental ingestion, where they indicate serious systemic absorption.

  • Safety Constraints: Official labeling advises caution for individuals with pre-existing conditions that may increase susceptibility to systemic effects. These include heart disease, high blood pressure (hypertension), thyroid disease, diabetes, and trouble urinating due to an enlarged prostate gland. The safety status for use during pregnancy and breast-feeding is not conclusively established in official documents.

  • Other Limitations: A high-level safety concern is noted regarding the interaction with Monoamine Oxidase Inhibitors (MAOIs), which may increase the risk of hypertension. Additionally, to prevent the transmission of infection, regulatory labeling advises against sharing the container.

Overdose and Emergency Response

The official regulatory documentation for Nesopine (Oxymetazoline hydrochloride) describes a specific set of clinical manifestations that may occur following an overdose, often resulting from excessive use or accidental oral ingestion. The overdose presentation typically involves effects on the Central Nervous System and the cardiovascular system. Initial signs may include features of CNS stimulation, such as fever, nervousness, or psychic disturbance, which can progress to serious CNS depression marked by somnolence, stupor, and loss of consciousness.

Cardiovascular effects are also documented, starting with hypertension and tachycardia, potentially shifting to severe hypotension and bradycardia, leading to outcomes like cardiac arrhythmia or cardiovascular failure. Other documented signs include mydriasis, cyanosis, and respiratory distress, such as apnoea.

Immediate medical help must be sought if accidental ingestion is suspected, particularly in young children, due to the high risk of systemic absorption and associated serious adverse events requiring hospitalization. Regulatory guidance mandates symptomatic and supportive treatment, which may include gastric lavage and the use of activated charcoal. Official labeling also explicitly notes that vasopressor drugs are contraindicated in the management of this overdose. No specific antidote is documented in the prescribing information.

Therapeutic Uses of Nesopine

What Nesopine Treats: Main Uses and Benefits

Nesopine is a pharmaceutical preparation that may be applied across therapeutic domains involving symptoms related to physical discomfort marked by acute or episodic changes. It may be part of symptomatic management, which contributes to improved comfort during periods when symptoms are more noticeable. Oxymetazoline may be used for the management of nasal discomfort associated with colds, allergies, and hay fever, as well as sinus congestion and pressure.

The medication is commonly used to help with conditions presenting with acute episodes, including the common cold, acute sinusitis, and seasonal allergies. It helps address symptom clusters that may become intense or disruptive, such as a stuffy nose, congestion, and associated pressure.

“Used during episodes of sudden symptom escalation, it assists with maintaining functional stability when nasal discomfort is high.”


Quick Fact: Relief for Congestion Nesopine may be applied in scenarios where symptoms intensify and supportive relief is needed, primarily addressing nasal stuffiness and contributing to a feeling of easier breathing.


In its ophthalmic form, Nesopine is relevant in clinical settings marked by symptoms related to inflammatory or irritative states, specifically addressing minor eye redness and irritation caused by environmental factors. This dual therapeutic support helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Nesina (Alogliptin)

This section outlines the eligibility and non-eligibility information as documented in official government regulatory sources, such as the FDA and EMA.

Contraindications and Restrictions

Classification Population/Condition Constraint Type
Contraindicated History of a serious hypersensitivity reaction to alogliptin or its excipients (e.g., angioedema, anaphylaxis) Absolute Exclusion
Use Not Authorized Patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis Limitation of Use
Use Not Recommended Patients with Severe Hepatic Impairment (Child-Pugh Class C) Lack of Safety Data

Conditional Use and Special Consideration

Eligibility is conditional for certain populations, requiring monitoring or dose adjustment based on regulatory labeling:

  • Renal Impairment: Patients with moderate or severe renal impairment or End-Stage Renal Disease (ESRD) must have a modified dose based on their kidney function. Appropriate assessment of renal function is mandatory before starting treatment.
  • Heart Failure: Use requires careful consideration of risks and benefits, especially in patients with a history of heart failure or renal impairment, and requires subsequent monitoring for worsening symptoms.
  • Pancreatitis: The medicine must be immediately discontinued if pancreatitis is suspected.

Age and Physiological Status

Safety and effectiveness are not established for pediatric use (patients under 18 years of age). There are no adequate and well-controlled studies for use during pregnancy or lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Nesopine (Oxymetazoline hydrochloride) is defined by its classification as a sympathomimetic agent, which presents a potential for significant pharmacodynamic interactions with specific drug classes. This information is derived exclusively from government regulatory prescribing documents.

Contraindicated Combinations and Timing

Co-administration of Nesopine with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This restriction is mandated due to the potential for a severe pressor interaction that carries a documented risk of acute hypertension. To mitigate this risk, Nesopine must not be administered during, or for a mandatory period of up to 14 days (two weeks) following, the cessation of MAOI therapy.

Other Pharmacodynamic Interactions

Other documented interactions are based on the potential for additive cardiovascular effects or antagonism of therapeutic action.

  • Tricyclic Antidepressants (TCAs) and Other Sympathomimetics: Co-use with TCAs or other sympathomimetic medicines, including certain anti-Parkinsonian drugs, may lead to possible additive cardiovascular toxicity, including the risk of hypertension and arrhythmias.
  • Antihypertensive Agents: Nesopine may antagonise the intended therapeutic effects of blood pressure lowering medicines, such as beta-blockers.

Pharmacokinetic and Substance Interactions

No specific interactions involving CYP450 enzymes, drug transporters, food, alcohol, or herbal products are explicitly documented in the official regulatory prescribing information for this medicine.

Mechanism of Action

Alpha-Adrenergic Receptor Activation

The drug’s primary mechanism involves acting as a direct-acting agonist on alpha-adrenergic receptors (alpha-adrenoceptors) within the nasal mucosal blood vessels. This initiates a signaling sequence coupled to Gq and Gi proteins, primarily resulting in a surge of intracellular calcium ( Ca^2+). This domain is critical as it initiates the vascular cascade necessary for the drug’s physiological action.

Vascular Tone Modulation and Contraction

Activation of the alpha-adrenoceptors drives the vascular smooth muscle cells into forceful contraction. This targets systems regulating vascular tone, leading to intense, localized vasoconstriction (narrowing) of the arterioles and venous sinusoids. This pathway is the direct cause of reduced blood flow into the mucosal lining.

Tissue De-engorgement Cascade

The resulting vasoconstriction triggers the final physiological effect: the de-engorgement or shrinkage of the swollen mucosal tissue by reducing blood volume in the area. This sequence directly lowers the nasal airway resistance (NAR), a physiological consequence within the targeted passages. Prolonged use, however, can lead to mechanism limitations such as receptor desensitization (tachyphylaxis).

Dosage and Administration Information

Nesopine (Oxymetazoline hydrochloride) is administered exclusively by topical application to the nasal passages or the eye, depending on the formulation. The medicine is available as a nasal solution or spray containing 0.05% oxymetazoline and as an ophthalmic solution typically at 0.025% concentration. These administration routes ensure the drug’s action is localized to the application site.

Standard Administration and Dosing

The standard regimen for the 0.05% nasal formulation is 2 to 3 sprays or drops in each nostril. This dose is to be repeated not more often than every 10 to 12 hours, establishing a maximum twice-daily frequency. Critically, the use of the nasal product is limited to a maximum duration of three consecutive days. For the ophthalmic solution, the standard dosing is 1 or 2 drops in the affected eye(s), which may be administered up to four times per day as needed.

Procedural Guidelines

Several procedural steps are recommended to ensure proper use. Before the first application, the nasal spray pump must be primed with a few test sprays. During application, the individual should not tilt the head backward. Guidelines also specify that the nasal dispenser should not be shared between individuals. Furthermore, the intranasal medication is designated for nasal use only and must not be ingested.

Age-Specific Use

For pediatric patients aged 6 to under 12 years, the same nasal dose of 2 to 3 sprays or drops in each nostril is used, and it is instructed that this administration be conducted with adult supervision. Use in children under 6 years of age requires prior consultation with a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nesopine

This section describes the research base for Oxymetazoline hydrochloride, the active ingredient in Nesopine. It summarizes the types of studies that exist and what was monitored by researchers, without making any claims about effectiveness or providing medical advice. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.


Evidence for Use in Temporary Relief of Nasal Congestion

Research for the nasal solution and spray was evaluated in studies exploring temporary nasal stuffiness. The evidence for this indication is primarily derived from short-term, vehicle-controlled Randomized Controlled Trials (RCTs). These studies were conducted during periods of increased symptom activity and primarily included adults and older children. Researchers examined outcomes related to physical discomfort, monitoring objective measurements of nasal airflow and collecting patient-reported outcomes describing perceived discomfort. Studies report patterns observed in the populations over periods ranging from a single application up to short-term treatment trials.


Evidence for Use in Acquired Blepharoptosis and Ocular Redness

The evidence base for the ophthalmic formulations was evaluated in studies focused on acquired eyelid droop (ptosis) and minor eye redness. For acquired ptosis, research centered on multiple medium-term, vehicle-controlled Phase 3 RCTs that included adult populations. The studies monitored measurements related to the height of the upper eyelid and outcomes reflecting daily functioning or activity level, such as the superior visual field. Research also describes short-term patterns related to eye redness observed in the studied populations.


Research Gaps and Areas of Uncertainty

This section synthesizes key areas where the evidence base is not yet complete. Follow-up durations were often limited to acute or medium-term periods, meaning long-term outcomes are not fully established. There is limited information regarding results over extended periods. Data for certain groups remain insufficient, including very young children and individuals with specific causes of ptosis or certain co-existing conditions. This overview highlights what is known—and what remains uncertain—in the research landscape for Nesopine's active ingredient.

Frequently Asked Questions (FAQ)

Common questions about Nesopine (FAQ)


Q: Is Nesopine considered a strong medication?

A: Official regulatory documents describe the active ingredient, oxymetazoline, as a potent synthetic substance. This potency relates to its function as a direct vasoconstrictor, meaning it works strongly and directly to narrow the blood vessels in the application area.

Q: Are there any common supplements or vitamins that interact with Nesopine?

A: Official regulatory prescribing information indicates that no specific interactions involving common vitamins or dietary supplements are explicitly documented. Disclosing all supplements and medicines being taken to a healthcare professional is considered a standard safety measure.

Q: How quickly does Nesopine start to work after taking it?

A: The drug's mechanism of action involves rapid vasoconstriction, which is the narrowing of blood vessels in the nasal or ocular tissue. This physical action leads quickly to the de-engorgement or shrinking of the swollen tissue, which is the physiological action intended to result in relief.

Q: How long do the effects of Nesopine typically last?

A: The drug’s administration frequency is typically noted to be every 10 to 12 hours. Some product labels describe the relief provided by one application as lasting up to 12 hours.

Q: Is Nesopine suitable for use in older adults?

A: Official labeling advises caution for individuals with pre-existing conditions like heart disease or high blood pressure. Since these conditions are more common in older adults, individuals with these conditions should consult with a healthcare provider to review their eligibility.

Q: What should I know about taking Nesopine and driving?

A: Nesopine is a topical product, but some product labels list potential systemic side effects such as dizziness or drowsiness. Safety guidelines suggest that individuals should assess their reaction to the medication before driving or operating heavy machinery.

Q: Is it safe to use Nesopine during pregnancy or while breastfeeding?

A: Official regulatory labeling indicates that the safety status for use during pregnancy and breast-feeding is not conclusively established. Regulatory documents state that use during these periods requires consultation with a health professional.

Q: What are the rare but serious side effects of Nesopine?

A: Documented serious systemic reactions are noted primarily in the context of overexposure or accidental ingestion of the product. These events include changes in heart rhythm such as an abnormally fast heartbeat (tachycardia) and a slow heartbeat (bradycardia).

Q: How does Nesopine affect my blood pressure?

A: Nesopine is a vasoconstrictor that is shown in clinical trials to increase blood pressure in some patients. Individuals with pre-existing high blood pressure (hypertension) are noted in safety materials as requiring caution.

Q: Why is Nesopine used for [secondary indication] when it’s mainly known for [primary indication]?

A: Official documents describe the active ingredient's use for two separate indications, depending on the product formulation. It is approved for the temporary relief of nasal congestion and, in specific ophthalmic (eye drop) formulations, for acquired blepharoptosis and ocular redness.

Q: Is it true that Nesopine can affect my mood?

A: Although the drug is administered topically, some systemic effects are reported, including nervousness and trembling. However, regulatory sources do not commonly report direct statements or warnings regarding mental or mood changes.

Q: Can children or teenagers be prescribed Nesopine?

A: The nasal formulation is indicated for use in children aged 6 years of age and older. Use in children under 6 years of age is subject to a review by a healthcare provider.

Q: Does Nesopine need to be taken with food, or can I take it on an empty stomach?

A: Nesopine is only administered as a topical liquid solution (nasal or ophthalmic). Since the product is administered as a topical liquid solution, the timing of food intake is not relevant to its use.

Q: What happens if I miss a dose of Nesopine?

A: If a dose is missed, patient information suggests using it as soon as it is remembered. If it is almost time for the next scheduled dose, the instruction is to skip the missed one and continue the regular schedule. The guidance is not to use extra medicine to compensate for the missed application.

Q: Are there any long-term effects associated with taking Nesopine?

A: Research shows that study follow-up periods are often limited, meaning long-term outcomes are not fully established. A specific risk is that frequent or prolonged use is documented to potentially cause nasal congestion to recur or worsen, a condition known as rhinitis medicamentosa.

Q: Can I drink alcohol while taking Nesopine, or should I avoid it?

A: Official regulatory prescribing information does not explicitly document a specific interaction with alcohol. Individuals should consult a healthcare provider regarding alcohol consumption while using any medicine.

Q: Where can I find official, unbiased information about Nesopine research?

A: Official labeling, such as that provided by the FDA through DailyMed, often includes links to Related Resources. These resources may include official government databases for Clinical Trials and literature repositories like PubMed, which contain public research data.

Q: How is Nesopine different from an over-the-counter medicine for similar symptoms?

A: Nesopine's active ingredient is a sympathomimetic that causes vasoconstriction, functioning as a topical decongestant. This specific physiological action is clinically recognized for providing relief that is superior to simple saline solutions alone.

Q: Does Nesopine come in different strengths or formulations?

A: Yes, the medicine is available in different strengths and forms designed for specific uses. These include a nasal solution or spray, typically containing 0.05% oxymetazoline, and an ophthalmic solution, typically at 0.025% concentration.

Q: Is Nesopine available in generic form?

A: The active ingredient in Nesopine, oxymetazoline hydrochloride, is a common compound. Because of its status, it is available in generic form and is widely found in various over-the-counter (OTC) nasal products.

Q: Is it safe to stop taking Nesopine suddenly?

A: The nasal formulation is officially limited to a maximum duration of three consecutive days of use. The short treatment period for the nasal formulation is limited to a maximum of three consecutive days of use, which reflects the short-term use pattern.

Q: Can Nesopine be crushed or split if the pill is too large?

A: This medicine is only available as a topical nasal solution, nasal spray, or ophthalmic solution. It is not manufactured or sold in a solid dosage form, such as a pill or tablet, that would need to be crushed or split.

Q: Are there restrictions on heavy machinery operation while taking Nesopine?

A: Although it is a topical product, some product labels list potential systemic side effects such as dizziness or drowsiness. Safety guidelines suggest that individuals should assess their reaction to the medication before operating heavy machinery.

Q: Is there any research on Nesopine and fertility?

A: Official resources, including fact sheets from the National Institutes of Health, indicate the current status of research on this topic. Specific studies to determine if the active ingredient affects a woman's or man's fertility have not been completed.

Q: What are the main things I should tell my doctor before starting Nesopine?

A: Patients are advised to inform a healthcare provider if they have certain pre-existing conditions that may increase susceptibility to systemic effects. These include heart disease, high blood pressure, thyroid disease, or diabetes, as well as if they have used MAOIs in the last 14 days.

Q: What should I do if I notice a change in my vision while taking Nesopine?

A: Blurred vision is a potential side effect listed on some product labels. This is particularly noted with the ophthalmic (eye drop) formulation, which is applied directly to the eye.

Q: Why do some people say Nesopine didn't work for them?

A: Studies and official evidence describe patterns observed in large groups of people during trials. Regulatory documents explicitly state that research findings do not determine whether an individual person will respond similarly to the group results.

Q: Is Nesopine generally considered well-tolerated?

A: The most common documented adverse reactions are mild and temporary local discomforts in the application area, such as burning, stinging, and sneezing. Serious systemic reactions are noted primarily in the context of overexposure or accidental ingestion.

How should Nesopine be stored and disposed of?

The official regulatory labeling for Nesopine (Oxymetazoline hydrochloride) defines mandatory requirements for storage and disposal to ensure safety and stability.

Storage Requirements

Condition Specification
Temperature Controlled Room Temperature: 20 to 25 C (68 to 77 F)
Protection Protect from light; Do not freeze
Container Must be kept tightly closed

Handling and Disposal

Child-Safety: The product must always be stored out of the reach of children.

Disposal: The safest method for discarding unused or expired medicine is through a drug take-back program or community collection site. Regulatory guidance instructs against flushing the medicine down the toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nesopine found in:

A-Z Index: